Catheter ablation plays key role in 2019 ESC Guidelines on tachycardia

More than 15 years went by since the last ESC Guidelines on tachycardia update, and although drug treatment for supraventricular tachycardia (SVT) has not fundamentally changed in the meantime, the new guidelines include changes and additions such as the important role of catheter ablation in SVT treatment. Prof. Josep Brugada (chairperson of the guidelines task force) reminded the audience how frequently the condition occurs [1]. “The prevalence of SVT is 2.25/1000 persons, its incidence 35/100,000 person-years. Women have a 2-fold higher risk of developing SVT than men; and in individuals aged 65 or older, the risk of developing SVT is 5 times greater than younger people.” The 2019 guidelines provide treatment recommendations for all types of SVT. Although, drug therapies have not significantly changed since the previous guidelines were published in 2003, Prof. Brugada mentioned that more evidence has come to light over the past decade concerning ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 10 October, 2019